NKTR
NEKTAR THERAPEUTICSCompany Information
- Company Name
- NEKTAR THERAPEUTICS
- CIK
- CIK0000906709
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- NKTR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NKTR
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-08-18
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 50,942
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 35,560,436
- Shares outstanding
- 33,054,865
- Ownership
- 107.58%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 1.60%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 39 | 150 | 15 | 41 | 43 | 39 | 44 | 30 | 28 | 49 | 35 | 65 | ||||||
| Available For Sale Securities Debt Securities Current | 645 | 419 | 231 | 229 | 133 | 180 | 211 | 214 | 243 | 241 | 268 | 308 | ||||||
| Other Assets Current | 55 | 20 | 21 | 11 | 11 | 11 | 6 | 9 | 8 | 11 | 10 | 9 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | 33 | - | - | - | - | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | 0 | 0 | 1 | 4 | 1 | 2 | ||||||
| Inventory Net | - | - | 0 | - | - | - | 0 | 0 | 14 | 16 | 16 | 15 | ||||||
| Assets Current | 739 | 589 | 266 | 281 | 187 | 230 | 261 | 286 | 295 | 320 | 331 | 399 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 339 | 163 | 0 | 0 | 0 | 2 | 14 | 5 | 19 | 37 | 26 | - | ||||||
| Property Plant And Equipment Net | - | - | 2 | 3 | 3 | 3 | 3 | 4 | 15 | 17 | 19 | 20 | ||||||
| Operating Lease Right Of Use Asset | - | - | 3 | 7 | 8 | 8 | 8 | 9 | 9 | 17 | 18 | 19 | ||||||
| Goodwill | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Equity Method Investments | - | - | 3 | 5 | 5 | 8 | 12 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 17 | 11 | 6 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | ||||||
| Assets | 1,095 | 763 | 280 | 301 | 208 | 256 | 304 | 308 | 343 | 396 | 398 | 442 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 25 | 10 | 11 | 16 | 14 | 18 | 12 | 9 | 6 | 9 | 10 | 3 | ||||||
| Treasury Stock Common Shares | - | - | 0 | 0 | 1 | 8 | 1 | 8 | 8 | 1 | 0 | - | ||||||
| Accrued Liabilities Current | 23 | 25 | 22 | 29 | 35 | 31 | 30 | 32 | 30 | 24 | 22 | 30 | ||||||
| Operating Lease Liability Current | 23 | 23 | 20 | 22 | 22 | 22 | 20 | 22 | 21 | 19 | 19 | 19 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | 5 | - | - | - | - | ||||||
| Liabilities Current | 71 | 58 | 54 | 66 | 71 | 71 | 61 | 68 | 57 | 52 | 51 | 52 | ||||||
| Operating Lease Liability Noncurrent | 56 | 61 | 65 | 70 | 74 | 78 | 83 | 87 | 91 | 95 | 99 | 102 | ||||||
| Other Liabilities Noncurrent | 8 | 8 | 9 | 5 | 6 | 7 | 7 | 7 | 8 | 4 | 5 | 5 | ||||||
| Liabilities | 192 | 187 | 191 | 216 | 232 | 243 | 243 | 259 | 264 | 269 | 267 | 283 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 4,751 | 4,382 | 3,850 | 3,809 | 3,667 | 3,664 | 3,660 | 3,655 | 3,650 | 3,644 | 3,608 | 3,601 | ||||||
| Treasury Stock Value | - | - | - | 0 | -3 | -3 | -3 | -3 | -3 | -3 | - | - | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -1 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | -6 | ||||||
| Retained Earnings Accumulated Deficit | -3,846 | -3,805 | -3,760 | -3,724 | -3,689 | -3,647 | -3,596 | -3,603 | -3,566 | -3,514 | -3,477 | -3,435 | ||||||
| Stockholders Equity | 903 | 576 | 90 | 85 | -24 | 14 | 61 | 49 | 80 | 127 | 131 | 159 | ||||||
| Liabilities And Stockholders Equity | 1,095 | 763 | 280 | 301 | 208 | 256 | 304 | 308 | 343 | 396 | 398 | 442 | ||||||
| Gannet Bio Chem | - | - | 0 | - | - | - | 12 | - | - | - | - | - | ||||||
| Related Party | -0 | 0 | 0 | -1 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 390 | 390 | 390 | 390 | 390 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 34 | 29 | 20 | 20 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | ||||||
| Shares Outstanding | 20 | 20 | 20 | 20 | 12 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | ||||||
| Stockholders Equity Note Stock Split Conversion Ratio1 | - | 0 | - | - | - | 0 | 0 | 0 | 0 | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNEKTAR THERAPEUTICS (NKTR) — SEC Financial Statements & Analysis
NEKTAR THERAPEUTICS (NKTR) is a pharmaceutical preparations company, incorporated in DE. NEKTAR THERAPEUTICS trades on Nasdaq as: NKTR. NEKTAR THERAPEUTICS (NKTR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, NEKTAR THERAPEUTICS carries a market cap of $2.31B, a P/E ratio of -14.69x, a P/B ratio of 2.56x, a P/S ratio of 42.27x, an enterprise value of $2.27B, and an EV/EBITDA multiple of -16.20x. On profitability, it posts a gross margin of 68.82%, an operating margin of -257.80%, a net margin of -287.84%, a Return on Equity (ROE) of -35.75%, a Return on Assets (ROA) of -24.12%, and a Return on Invested Capital (ROIC) of -35.22%. Per share, it reports EPS of $-4.75, diluted EPS of $-4.75, free cash flow per share of $-7.08, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -27.15% year-over-year, net income growth of 28.51% year-over-year, and EPS growth of -45.23% year-over-year. On the balance sheet, it maintains a current ratio of 10.42x, a quick ratio of 10.42x, working capital of $668.42M, a debt-to-equity ratio of 0.21x, a debt ratio of 0.18, free cash flow of $-234.03M (TTM), and net debt of $-39.27M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.31B
- P/E TTM
- -14.69x
- EPS TTM
- $-4.75
- P/B TTM
- 2.56x
- ROE TTM
- -35.75%
- ROA TTM
- -24.12%
- Debt To Equity
- 0.21x
- Free Cash Flow TTM
- $-234.03M
- Net Revenue TTM Growth 1Y
- -27.15%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is NEKTAR THERAPEUTICS in?
NEKTAR THERAPEUTICS (NKTR) operates in the Pharmaceutical Preparations industry.
What exchange does NKTR trade on?
NEKTAR THERAPEUTICS (NKTR) trades on the Nasdaq.
Where is NEKTAR THERAPEUTICS incorporated?
NEKTAR THERAPEUTICS is incorporated in DE.
When was NEKTAR THERAPEUTICS (NKTR)'s most recent SEC filing?
NEKTAR THERAPEUTICS (NKTR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is NKTR's market cap?
NEKTAR THERAPEUTICS (NKTR) has a market capitalization of $2.31B as of 2026-06-30.
What is NKTR's EPS (earnings per share)?
NEKTAR THERAPEUTICS (NKTR)'s trailing twelve month EPS is $-4.75 as of 2026-06-30.
What is NKTR's ROE (return on equity)?
NEKTAR THERAPEUTICS (NKTR)'s trailing twelve month Return on Equity (ROE) is -35.75% as of 2026-06-30.
What is NKTR's ROA (return on assets)?
NEKTAR THERAPEUTICS (NKTR)'s trailing twelve month Return on Assets (ROA) is -24.12% as of 2026-06-30.
What is NKTR's ROIC (return on invested capital)?
NEKTAR THERAPEUTICS (NKTR)'s trailing twelve month Return on Invested Capital (ROIC) is -35.22% as of 2026-06-30.
What is NKTR's EV/EBITDA?
NEKTAR THERAPEUTICS (NKTR)'s trailing twelve month EV/EBITDA is -16.20x as of 2026-06-30.